Merrill reiterates New River at buy

New River Pharmaceuticals Inc. was reiterated by Merrill Lynch analyst David Munno at buy. From recent data on A01 and A03 studies, the analyst is confident that NRPH104 is less abusable than amphetamine. As a result, it should receive schedule 3 or 4 when approved. Shares of the Radford, Va.-based specialty pharmaceutical company were down 41 cents, or 1.43%, at $28.26 on volume of 563,607 shares versus the three-month running average of 295,217 shares. (Nasdaq: NPRH)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.